Moderate

Primary hyperparathyroidism (PHPT; parathyroid adenoma)

calcium-bone · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Autonomous PTH overproduction (single adenoma ~85%, hyperplasia, rarely carcinoma) causing hypercalcaemia with inappropriately normal/high PTH. Commonest cause of outpatient hypercalcaemia; often asymptomatic on routine bloods. 'Stones, bones, abdominal groans, psychic moans'. (Acute hypercalcaemic crisis is a separate critical entry.)

Red flags

  • Calcium >3.5 mmol/L, confusion, dehydration, arrhythmia — treat as hypercalcaemic crisis (critical pathway)
  • Very high calcium + very high PTH + neck mass — consider parathyroid carcinoma
  • Acute pancreatitis or renal colic as presenting feature
  • Rapid rise in calcium with weight loss (suspect malignancy instead)

Assessment

Differential diagnosis

  • Malignancy-associated hypercalcaemia (PTHrP, bony mets — PTH SUPPRESSED)
  • Familial hypocalciuric hypercalcaemia (FHH) — low urine calcium, family history, do NOT operate
  • Secondary/tertiary hyperparathyroidism (CKD)
  • Vitamin D toxicity, granulomatous disease, thiazides, lithium, milk-alkali
  • Thyrotoxicosis, immobilisation, adrenal insufficiency

Investigations

  • Corrected calcium (raised) + PTH (inappropriately normal or high) — the diagnostic pair
  • Phosphate (low/low-normal), magnesium, ALP, U&E/eGFR
  • 25-OH vitamin D (correct deficiency — it masks severity and worsens bone disease)
  • 24-hour urinary calcium + calcium:creatinine clearance ratio (low ratio <0.01 suggests FHH)
  • DEXA bone density (including distal 1/3 radius — cortical loss), renal tract ultrasound/CT for nephrocalcinosis/stones
  • Localisation ONLY once surgery planned: sestamibi scan +/- neck ultrasound +/- 4D-CT

Management

  • Confirm diagnosis (Ca + PTH); exclude FHH before any surgery (urine calcium, family history)
  • Correct vitamin D deficiency cautiously and ensure adequate hydration
  • Assess end-organ disease: renal function, stones/nephrocalcinosis, bone density, fragility fractures
  • Refer for parathyroidectomy if: symptomatic, Ca >0.25 mmol/L above upper limit, age <50, eGFR <60, nephrolithiasis/nephrocalcinosis, or T-score ≤ -2.5 / fragility fracture
  • If not operated: monitor calcium, renal function and DEXA; maintain hydration and normal calcium/vitamin D intake
  • Cinacalcet to control calcium when surgery declined/unsuitable or in parathyroid carcinoma
  • Address osteoporosis with bisphosphonate/denosumab if surgery not performed

Drugs & doses

IV 0.9% saline rehydration if significantly hypercalcaemic/symptomatic (see hypercalcaemia entry for crisis doses)
Cinacalcet 30 mg PO bd, titrate to calcium (max 90 mg bd) — when surgery not an option or carcinoma
Colecalciferol to replete deficiency (e.g. 800-2000 IU/day maintenance) with calcium monitoring
Alendronate 70 mg PO weekly or denosumab 60 mg SC 6-monthly for associated osteoporosis if not operated [verify local]
Avoid thiazides and lithium (raise calcium); ensure good hydration

Disposition

Outpatient endocrine/endocrine-surgery pathway. Admit for hypercalcaemic crisis, severe symptoms, or acute pancreatitis. Surgery is the only cure.

Complications & pitfalls

  • Nephrolithiasis, nephrocalcinosis, CKD
  • Osteoporosis / osteitis fibrosa cystica, fragility fractures
  • Hypercalcaemic crisis, acute pancreatitis, peptic ulcer
  • Post-op hungry bone syndrome (profound hypocalcaemia), recurrent laryngeal nerve injury

Exam pearls

  • The diagnosis is clinched by a raised calcium with a non-suppressed PTH — in malignancy PTH is suppressed.
  • Always exclude FHH (24-h urine calcium, calcium:creatinine clearance ratio <0.01, family history) — surgery does not help and may harm.
  • Correct vitamin D deficiency before judging severity; it unmasks higher PTH/bone turnover.
  • Watch for hungry bone syndrome after parathyroidectomy in patients with high bone turnover — replace calcium and vitamin D.
  • Measure distal radius on DEXA — PHPT preferentially causes cortical bone loss.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.